Stryker Corporation $SYK Holdings Raised by Continuum Advisory LLC

Continuum Advisory LLC increased its position in shares of Stryker Corporation (NYSE:SYK) by 413.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,937 shares of the medical technology company’s stock after purchasing an additional 6,390 shares during the quarter. Continuum Advisory LLC’s holdings in Stryker were worth $2,499,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. VanderPol Investments L.L.C. raised its holdings in shares of Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after purchasing an additional 28 shares during the period. KCM Investment Advisors LLC boosted its holdings in shares of Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after buying an additional 28 shares during the period. Rossby Financial LCC boosted its holdings in shares of Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after buying an additional 28 shares during the period. Tcfg Wealth Management LLC grew its position in shares of Stryker by 2.7% during the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after buying an additional 29 shares during the last quarter. Finally, ICW Investment Advisors LLC grew its position in shares of Stryker by 0.6% during the 4th quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company’s stock valued at $1,791,000 after buying an additional 30 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In other news, insider Debra King sold 826 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 300,000 shares of Stryker stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the sale, the director owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 351,267 shares of company stock valued at $118,197,701. Company insiders own 4.60% of the company’s stock.

Stryker Stock Performance

SYK opened at $312.10 on Thursday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $329.60 and its 200-day moving average is $330.33. The stock has a market cap of $119.71 billion, a PE ratio of 32.34, a price-to-earnings-growth ratio of 1.99 and a beta of 0.76. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same period in the prior year, the company posted $3.13 EPS. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts predict that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio is presently 36.48%.

Analyst Ratings Changes

SYK has been the topic of a number of recent research reports. UBS Group initiated coverage on shares of Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 target price on the stock. JPMorgan Chase & Co. lowered their target price on Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Wolfe Research cut Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Argus set a $370.00 price target on Stryker in a report on Thursday, July 9th. Finally, Evercore set a $350.00 price objective on Stryker in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Director Mary Brainerd purchased additional Stryker shares on September 2, increasing her personal stake. Insider buying can signal confidence in the company’s valuation and outlook, although the purchase alone is unlikely to materially change earnings expectations. Stryker Insider Makes Bold New Move With Fresh Share Purchase
• Positive Sentiment: Stryker received FDA De Novo authorization for SportSuite Vision, its surgical application for Apple Vision Pro, and completed the first reported hip arthroscopy using the system. The technology could strengthen Stryker’s digital-surgery and orthopedic innovation offerings, though commercial adoption remains to be demonstrated. Stryker introduces FDA-authorized surgical application for Apple Vision Pro
• Positive Sentiment: Stryker agreed to acquire ZuriMED, adding the FiberLocker System and expanding its shoulder-care and rotator-cuff portfolio. The deal could broaden Stryker’s orthopedic product lineup and growth opportunities. Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio
• Neutral Sentiment: Analysts remain broadly optimistic about Stryker’s longer-term prospects even as the shares have underperformed the broader market. The company’s latest reported quarter exceeded earnings expectations, but its valuation remains relatively elevated, which can increase sensitivity to growth concerns. Is Stryker Stock Underperforming the Nasdaq?
• Negative Sentiment: The recent underperformance suggests investors may be focused more on valuation, execution, and market-wide factors than on the new product announcements. The ZuriMED transaction also introduces integration and spending risks, with financial terms and its near-term earnings contribution not specified in the available reports.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.